Sonntag 22. Juni 2014, 14:57
Sonntag 22. Juni 2014, 17:52
Rolland et al. hat geschrieben:Competing Interests: Dr ROLLAND is the main investigator in a clinical trial funded by
ETHYPHARM, which is developing a labelled form of baclofen for alcohol use disorders.
Dr PAILLE has received sponsorship to attend scientific meetings, speaker honoraria, and
consultancy fees from Lundbeck, Ethypharm, D&A Pharma, and Merck-Serono.
Dr FLEURY has received sponsorship to attend scientific meetings from Lundbeck.
Dr COTTENCIN is an associate Investigator in the ALPADIR clinical trial, comparing HDB
vs. placebo for abstinence maintenance, which is funded by ETHYPHARM.
He has received sponsorship to attend scientific meetings from Lundbeck, BMS
Otsuka, Janssen Cilag, Reckitt Benckiser, Pfizer, Bouchara Recordati.
Dr BENYAMINA has received sponsorship to attend scientific meetings, speaker honoraria,
and consultancy fees from Merck-Serono, BMS, Reckitt-Benckiser Pharma, and Otsuka.
Dr Benyamina is a member of the Lundbeck scientific board in France for Selincro.
Dr AUBIN has received sponsorship to attend scientific meetings, speaker honoraria, and
consultancy fees from Bioprojet, D&A Pharma, Ethypharm, Lundbeck, Merck-Serono,
Novartis, and Pfizer.
Sonntag 22. Juni 2014, 19:41
Ich bin persönlich alles andere als davon überzeugt, dass sich die beiden Studien (Bacloville und Alpadir) wirklich „konkurrieren“. Think positive!Federico hat geschrieben:Bacloville und Alpadir, die beiden konkurrierenden Studien …